RayKnowChina Research Map
Shortlist0

ChongqingArmy Medical University

Xinqiao Hospital, Army Medical University

陆军军医大学第二附属医院(新桥医院)

Listed for 13 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Xinqiao Hospital, Army Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led1 open trial led
  2. Hepatocellular carcinoma肝细胞癌23 papers led
  3. Stomach cancer胃癌18 papers led
  4. Hepatoblastoma肝母细胞瘤0 papers led
  5. Osteosarcoma骨肉瘤5 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Multiple myeloma多发性骨髓瘤5 papers led
  8. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病3 papers led
  9. Haemophilia A血友病 A0 papers led
  10. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  11. Alport syndromeAlport 综合征2 papers led
  12. IgA nephropathyIgA 肾病4 papers led
  13. Congenital diaphragmatic hernia先天性膈疝2 papers led

Not listed for: Oesophageal squamous cell carcinoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Chongqing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2022-03
    Registry
    NCT05147844

    Age 18 years to 75 years (registered criteria)

    Led by Xinqiao Hospital, Army Medical UniversityChongqing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgery
Papers it led3
  1. Evaluation of target autocrop function in nasopharyngeal carcinoma SIB IMRT plan.2022Physical and engineering sciences in medicine
  2. BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells.2021Investigational new drugs
  3. A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
All its trials on ClinicalTrials.gov, any status5
  1. Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT05147844Lead sponsorPhase 2Start 2022-03
  2. EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal CarcinomaCompletedNCT04509726Lead sponsorPhase 1/Phase 2Start 2023-03
  3. Using Massage of Maxillofacial and Oral Cavity to Prevent Radioactive Oral MucositisCompletedNCT03788499Lead sponsorN/AStart 2019-01
  4. 3DV+TPS Applied to Radiotherapy for Nasopharyngeal CarcinomaCompletedNCT03791944Lead sponsorN/AStart 2018-12
  5. 3DV+TPS Software Outlines the Radiotherapy of Nasopharyngeal CarcinomaCompletedNCT03810274Lead sponsorStart 2012-02
More papers found outside PubMed (not counted)3
  1. TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.2023Journal of Clinical Oncologyconference-abstract
  2. Use of Chinese Visible Human Images to Enhance the Interpretation of CT or MRI Images: Application to Nasopharyngeal Structures Segmentation in the Treatment Planning System2022Iranian Red Crescent Medical Journalarticle
  3. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 23 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
23
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 4420222023: 3320232024: 5520242025: 662025

5 hospitals in Chongqing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesSurgery & liver transplantImaging, AI & early detectionRecurrence & prognosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatology
Papers it led23
  1. RNASET2 Deficiency Induces Hepatocellular Carcinoma Metastasis through Cholesterol-Triggered MET Activation.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Application of laparoscopic liver surgery techniques in laparoscopic thermal ablation of liver tumors.2025BMC gastroenterologyFree full text
  3. A new strategy of laparoscopic anatomical right hemihepatectomy via a hepatic parenchymal transection-first approach guided by the middle hepatic vein.2025Bioscience trends
  4. POLD1 identification as a potential prognostic and immunotherapeutic biomarker for hepatocellular carcinoma.2025International journal of biological macromolecules
  5. Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression.2025Journal for immunotherapy of cancerFree full text
  6. L-methionine promotes CD8+ T cells killing hepatocellular carcinoma by inhibiting NR1I2/PCSK9 signaling.2025Neoplasia (New York, N.Y.)Free full text
  7. Radiomic Analysis Based on Gd-EOB-DTPA Enhanced MRI for the Preoperative Prediction of Ki-67 Expression in Hepatocellular Carcinoma.2024Academic radiology
  8. A Dynamic Online Nomogram Based on Gd-EOB-DTPA-Enhanced MRI and Inflammatory Biomarkers for Preoperative Prediction of Pathological Grade and Stratification in Solitary Hepatocellular Carcinoma: A Multicenter Study.2024Academic radiology
  9. WDR4 promotes HCC pathogenesis through N7-methylguanosine by regulating and interacting with METTL1.2024Cellular signalling
  10. Intrahepatic Glisson Intrathecal Dissection via a Hepatic Parenchymal Transection-First Approach for Laparoscopic Anatomical Hemihepatectomy in Patients with Left/Right Glisson Pedicle Involvement.2024Journal of laparoendoscopic & advanced surgical techniques. Part A
  11. Multiphase MRI-Based Radiomics for Predicting Histological Grade of Hepatocellular Carcinoma.2024Journal of magnetic resonance imaging : JMRI
  12. A safe and simple exposure and Pringle maneuver in laparoscopic anatomical liver resection of segment 7.2023BMC gastroenterologyFree full text
  13. Cu2-xSe nanoparticles suppress cell proliferation and migration in hepatocellular carcinoma by impairing mitochondrial respiration.2023Biomedical materials (Bristol, England)
  14. Laparoscopic surgical management of hepatocellular carcinoma patients with diaphragmatic involvement.2023Surgical endoscopy
  15. Laparoscopic liver resection of segment 8 via a hepatic parenchymal transection-first approach guided by the middle hepatic vein.2022BMC gastroenterologyFree full text
  16. OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression.2022Cancer immunology, immunotherapy : CIIFree full text
  17. Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma.2022Molecular cancerFree full text
  18. Small-Diameter Drug-Eluting Beads-Based Transarterial Chemoemboli-zation (DEB-TACE) for Treating Patients With Esophageal Cancer With Acute Bleeding.2022The American journal of gastroenterology
  19. Identification and analysis of immune-related subtypes of hepatocellular carcinoma.2021Experimental biology and medicine (Maywood, N.J.)Free full text
  20. Integrated LC-MS metabolomics with dual derivatization for quantification of FFAs in fecal samples of hepatocellular carcinoma patients.2021Journal of lipid researchFree full text
  21. Laparoscopic anatomic liver resection of segment 7 using a caudo-dorsal approach to the right hepatic vein.2021Surgical oncology
  22. FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.2021TheranosticsFree full text
  23. Liver Parenchyma Transection-First Approach for Laparoscopic Left Hemihepatectomy: A Propensity Score Matching Analysis.2021World journal of surgery
All its trials on ClinicalTrials.gov, any status1
  1. Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT03084380Lead sponsorPhase 1/Phase 2Start 2017-06

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 18 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 5520212022: 7720222023: 5520232024: 0020242025: 112025

6 hospitals in Chongqing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyNutrition & recoveryPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Nephrology

Over half of these papers are lab or animal studies.

Papers it led18
  1. Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a "hit-and-run" paradigm.2025Cancer communications (London, England)Free full text
  2. In Vivo Anchoring Bis-Pyrene Probe for Molecular Imaging of Early Gastric Cancer by Endoscopic Techniques.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Magnifying image-enhanced endoscopy-only mode boosted early cancer diagnostic efficiency: a multicenter randomized controlled trial.2023Gastrointestinal endoscopyRCT
  4. RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer.2023JCI insightFree full text
  5. FOXM1 increases hTERT protein stability and indicates poor prognosis in gastric cancer.2023Neoplasia (New York, N.Y.)Free full text
  6. The hTERT-p50 homodimer inhibits PLEKHA7 expression to promote gastric cancer invasion and metastasis.2023OncogeneFree full text
  7. Arsenic sulfide inhibits the progression of gastric cancer through regulating the circRNA_ASAP2/Wnt/β-catenin pathway.2022Anti-cancer drugsFree full text
  8. Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer.2022BMC cancerFree full text
  9. Helicobacter pylori infection induces stem cell-like properties in Correa cascade of gastric cancer.2022Cancer letters
  10. Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy.2022Clinical and translational medicineFree full text
  11. Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification.2022Molecular cancerFree full text
  12. NCX1 coupled with TRPC1 to promote gastric cancer via Ca2+/AKT/β-catenin pathway.2022OncogeneFree full text
  13. Single-incision plus one-port laparoscopic gastrectomy versus conventional multi-port laparoscopy-assisted gastrectomy for gastric cancer: a retrospective study.2022Surgical endoscopy
  14. Helicobacter pylori-Induced Heparanase Promotes H. pylori Colonization and Gastritis.2021Frontiers in immunologyFree full text
  15. Human telomerase reverse transcriptase (hTERT) synergistic with Sp1 upregulate Gli1 expression and increase gastric cancer invasion and metastasis.2021Journal of molecular histology
  16. Development of a long noncoding RNA BC032469-dependent gold nanoparticle molecular beacon for the detection of gastric cancer cells.2021Nanomedicine (London, England)
  17. Role of heparanase 2 (Hpa2) in gastric cancer.2021Neoplasia (New York, N.Y.)Free full text
  18. Early Malignant Gastric Adenomyoma: A Rare Case.2021The American journal of gastroenterology
All its trials on ClinicalTrials.gov, any status2
  1. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNCT06128252Study siteN/AStart 2024-09
  2. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total GastrectomyStatus unknownNCT02110628Study sitePhase 3Start 2014-08

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Chongqing for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 5 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 1120232024: 0020242025: 112025

23 hospitals in Chongqing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led5
  1. Screening and identification Hub genes associated with immune cell infiltration and critical biomarkers in osteosarcoma.2025Molecular and cellular probes
  2. Long noncoding RNA XLOC_006786 inhibits the proliferation, invasion and metastasis of osteosarcoma cells through NOTCH3 signaling pathway by targeting miR-491-5p.2023Human cell
  3. WIPI1 promotes osteosarcoma cell proliferation by inhibiting CDKN1A.2021Gene
  4. A New Recombinant Fibronectin/Cadherin Protein-Hydrophobically Modified Glycol Chitosan/Paclitaxel Layer-By-Layer Self-Assembly Strategy for the Postoperative Therapy of Osteosarcoma and Correlated Bone Injury.2021Journal of biomedical nanotechnology
  5. Association of RDM1 with osteosarcoma progression via cell cycle and MEK/ERK signalling pathway regulation.2021Journal of cellular and molecular medicine
Earlier papers (2016–2020)6
  1. Anoikis‑resistant human osteosarcoma cells display significant angiogenesis by activating the Src kinase‑mediated MAPK pathway.2019Oncology reports
  2. CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma.2019Proceedings of the National Academy of Sciences of the United States of America
  3. TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis.2018Journal of experimental & clinical cancer research : CR
  4. Downregulation of tumor suppressing STF cDNA 3 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by the Wnt/GSK-3β/β-catenin/Snail signaling pathway.2016Cancer letters
  5. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets.2016Cancer letters
  6. RanBP9/TSSC3 complex cooperates to suppress anoikis resistance and metastasis via inhibiting Src-mediated Akt signaling in osteosarcoma.2016Cell death & disease

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Chongqing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Long-term outcomes of endoscopic resection of gastric GISTs.2017Surgical endoscopy

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 112025

4 hospitals in Chongqing for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance
Departments in papersRadiology / nuclear medicine
Papers it led5
  1. Transcriptome Analysis Identifies Functional and Prognostic Hypoxia-Associated Genes in Multiple Myeloma.2026International journal of laboratory hematology
  2. Identification of Copy Number Alterations From Shallow Whole-Genome Sequencing in Multiple Myeloma.2025Hematological oncology
  3. Prognostic value of semi-quantitative parameters of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients.2023Annals of nuclear medicineFree full text
  4. Lactate Decreases Bortezomib Sensitivity and Predicts Poor Clinical Outcomes of Multiple Myeloma.2023Current medical science
  5. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.2023Journal of hematology & oncologyFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple MyelomaStatus unknownNCT05008536Lead sponsorEarly phase 1Start 2021-10
  2. Anti-BCMA CAR-T Cell Therapy for the R/R Multiple MyelomaStatus unknownNCT04637269Lead sponsorEarly phase 1Start 2020-11
  3. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  4. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  5. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  6. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  7. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  8. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309Study siteStart 2013-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 3 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.3%.

Papers led
3
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

3 hospitals in Chongqing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05579132

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCAR-T & cell therapyMRD & relapseChildren

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

4 hospitals in Chongqing for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Study siteStart 2024-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Chongqing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Severe lupus nephritis in pregnancy complicated with thrombotic thrombocytopenic purpura: Successful treatment with plasma exchange and renal replacement therapy.2020Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
All its trials on ClinicalTrials.gov, any status1
  1. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Study siteStart 2024-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 2 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 3.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Chongqing for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 112025

14 hospitals in Chongqing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 2 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 3.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

2 hospitals in Chongqing for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

陆军军医大学第二附属医院(新桥医院)

Xinqiao Hospital, Army Medical University

重庆

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Xinqiao Hospital; Second Affiliated Hospital of Army Medical University; Xinqiao Hospital of Army Medical University; Xinqiao Hospital of Third Military Medical University; Second Affiliated Hospital of Third Military Medical University; Second Affiliated Hospital, Third Military Medical University; 新桥医院

Suggest a correctionDownload the data